Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

William Looney

Executive Editor

New York, NY
Set Alert for Articles By William Looney

Latest From William Looney

Bayer US Pharmaceuticals’ Sebastian Guth: Designs On A New Decade

Bayer’s ambitious campaign to reposition itself as a global leader in two complementary fields – health and nutrition – will face its toughest test in the US, with its highly litigious approach to product liability and a tendency to target pharmaceuticals as the source of the health system’s affordability and access problems.

Outlook 2020 Leadership

Gates MRI CEO Penny Heaton Speaks …

Insights from Gates Medical Research Institute CEO Dr. Penny Heaton. 

C-Suite Speaks Market Access

Gates Foundation Plots A Fresh Metric For Market Access: Lives Saved

In Vivo visits Gates Medical Research Institute CEO Dr. Penny Heaton to review its first pipeline of drugs and vaccines to attack four of the world’s biggest killers: TB, malaria, enteric diseases and other conditions affecting maternal, newborn and child health.

C-Suite Speaks Leadership

Market Access 2020: Understanding US Payer Expectations

Big pharma is facing a difficult US competitive landscape as its traditional customers realign to build their own redoubts of size, scale and reach.

Market Access Strategy

How Proximity Creates Partnerships

Former Amgen R&D lead Sean Harper talks exclusively to In Vivo about his new role as a venture capitalist, joining veteran industry investor Beth Seidenberg as co-founder of Los Angeles-based Westlake Village BioPartners.

Business Strategies Deals

Corporate Affairs: Biopharma’s First Line Of Defense Against Scrutiny

Amgen’s Judy Gawlik Brown is using her finance and consumer health background to make the big biotech’s message more authentic and accessible – a brisk reset against today’s disconnected world of alternative facts.

C-Suite Speaks Leadership
See All
UsernamePublicRestriction

Register